Schrödinger Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors

▤ Summary

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors. “ Throughout her career, Nancy has been celebrated not only for her R&D breakthroughs, but for her leadership of both scientific and business strategies for biotech and pharmaceutical companies,” said Schrödinger CEO Ramy Farid, Ph.D. “ As we expand our partnerships globally and grow our proprietary drug discovery pipeline, Nancy’s drug development experience and unique knowledge of the biopharma ecosystem will be an important asset for our board.” Ms. Thornberry currently serves as the Chief Executive Officer of Kallyope, a platform biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis. Prior to joining Kallyope, Ms. Thornberry served in roles of increasing responsibility at Merck & Co, Inc., including as Senior Vice President and Franchise Head, Diabetes and Endocrinology. During her career at Merck, Ms. Thornberry initiated and led multiple drug discovery and development programs, including Merck’s dipeptidyl peptidase 4 (DPP-4) inhibitor (marketed as JANUVIA®) for the treatment of Type 2 diabetes. “ I look forward to working with the team to help guide the next phase of Schrödinger’s growth.” About Schrödinger Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide.

▦ Linked Companies

Schrödinger

$100M to $250M